Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the safety and tolerability of five doses of PBF-680 (5 mg, 10 mg, 20 mg, 40 mg and 60mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.

NCT02635945

Asthma

COMPLETED PHASE2

Study to Evaluate GSK2190915 in Subjects With Mild Asthma

NCT00812773

Asthma

COMPLETED PHASE2

Study of Multiple Ascending Dose of KBL693 in Healthy Participants

NCT04307173

Moderate to Severe Asthma

COMPLETED PHASE1

Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)

NCT00242307

Bronchial Asthma

COMPLETED PHASE2/PHASE3

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794

Asthma Patients

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PBF-680 (5 mg)

5 mg of PBF-680

Group Type EXPERIMENTAL

PBF-680

Intervention Type DRUG

5, 10, 20, 40 and 60 mg of PBF-680

PBF-680 (10 mg)

10 mg of PBF-680

Group Type EXPERIMENTAL

PBF-680

Intervention Type DRUG

5, 10, 20, 40 and 60 mg of PBF-680

PBF-680 (20 mg)

20 mg of PBF-680

Group Type EXPERIMENTAL

PBF-680

Intervention Type DRUG

5, 10, 20, 40 and 60 mg of PBF-680

PBF-680 (40 mg)

40 mg of PBF-680

Group Type EXPERIMENTAL

PBF-680

Intervention Type DRUG

5, 10, 20, 40 and 60 mg of PBF-680

PBF-680 (60 mg)

60 mg of PBF-680

Group Type EXPERIMENTAL

PBF-680

Intervention Type DRUG

5, 10, 20, 40 and 60 mg of PBF-680

Placebo

Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo for the dose of 5, 10, 20 and 40 mg of PBF-680

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PBF-680

5, 10, 20, 40 and 60 mg of PBF-680

Intervention Type DRUG

Placebo

placebo for the dose of 5, 10, 20 and 40 mg of PBF-680

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male or females subjects, 18-45 years (inclusive) of age at the time of enrollment.
2. Females must be of non-childbearing potential (i.e., surgically sterile) or have to use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault cap with spermicide until 28 days post-administration. Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide, in addition to having their female partner use some contraceptive measures until 28 days post-administration.
3. Clinically acceptable blood pressure and pulse rate in supine and standing position. Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
4. Body weight within normal range (Quetelet's index between 19 and 26) expressed as weight (kg) / height (m2).
5. Able to understand the nature of the study and comply with all their requirements.
6. Free acceptance to participate in the study by obtains signed informed consent form approved by the Ethics Committee of the Hospital (CEIC).

Exclusion Criteria

* Subjects meeting any of the following criteria at screening visit will be excluded from entry into the study:

1. History of serious adverse reactions or hypersensitivity to any drug.
2. Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
3. Background or clinical evidence of chronic diseases.
4. Acute illness two weeks before drug administration.
5. Having undergone major surgery during the previous 6 months.
6. Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication.
7. History of alcohol dependence or drug abuse in the last 5 years or daily consumption of alcohol \> 40 g for men or 24 gr/day for women or high consumption of stimulating beverages (\> 5 coffees, teas or coca cola drinks/ day) for both sexes.
8. Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
9. Need of any prescription medication within 14 days prior to the administration of the drug and non prescription medication or herbal medicines within 7 days prior to the administration of the drug.
10. Participation in other clinical trials during the previous 90 days in which an investigational drug or a commercially available drug was tested.
11. Having donated blood during 4 weeks period before inclusion in the study.
12. Existence of any surgical or medical condition which might interfere with the absortion, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
13. 12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec, bradychardia (\<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
14. Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.
15. History of hepatitis HBV and / or HCV and / or positive serology results which indicate the presence of hepatitis B surface antigen and / or detectable HCV ribonucleic acid (RNA).
16. Positive results from the HIV serology.
17. Females with positive results from the pregnancy test or breast-feeding.
18. Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation.
19. Positive results of the drugs at screening period or the day before starting treatment period. A minimum list of 6 drugs will be screened for inclusion: Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the Principal Investigator).
20. Known hypersensitivity to the study drug or the composition of the galenical form.
21. History of psychiatric diseases or epileptic seizures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes